Jump to content

All Activity

This stream auto-updates

  1. Past hour
  2. John Judd's Methods in Immunohematology is an excellent resource for procedures.
  3. Today
  4. donellda

    Ortho Optix

    I have no experience with this reader but it sounds like a nice solution for blood banks that do not have a Vision or other instrumentation.
  5. This is an old topic; validation protocol may now be available directly from the manufacturer or AABB should be able to provide guidance.
  6. @Beth Eades This is an old post, but wanted to see if you could update whether you still happened to have this amazing donor coming in! I'm sure with all the shortages this would be great to add to a resource book.
  7. While Malcolm is correct, I also agree with OneMore. I have worked with Immucor instrumentation for 17+ years, and always ruled out with a "double dose" cell, and never had issues.
  8. I apologize, I have never used Softbank, but I am familiar with reconstituted RBCs. I assume when you say Reconstituted RBCS, you are talking about adding plasma to red cells to get a desired hematocrit. The attachments is from the ICCBBA website. It tells you how to get an FDA compliant product label for reconstituted red blood cells. https://www.iccbba.org/uploads/b3/03/b303897194221c1b11b7637c5b3812f0/Reconstituted-Red-Blood-Cells.pdf Also, there are simple math formulas to figure out how much plasma you need to add to RBCs in order to get a desired hematocrit. But your software should be able to handle the math, all you need are the numbers for your product label. Reconstituted-Red-Blood-Cells.pdf
  9. This is an old post, but in case anyone needs the CDC Malaria risk information here is the link to the list of countries, recommendations, maps, etc.: https://www.cdc.gov/malaria/travelers/country_table/a.html
  10. Yesterday
  11. This is an old post, but thank you for this website! I am always interested in the differences in protocols by country or organization - you just never know when you'll find a bit of good information or good practice to incorporate with your own facility.
  12. This is an old post, and there are definitely changes to the catalog of software available for standalone cellular therapy labs. If anyone needs updated information, please put in a new request with as much detail as possible (scope of services, needs, wish list of features) and hopefully we can provide good updated information for you.
  13. Erythrocytes cannot be either homozygous or heterozygous (or hemizygous for that matter). The terms homozygous, heterozygous and hemizygous should only be used when referring to genes, and, while antigens are (ultimately) derived from genes, many, such as A, B, H, I, i, Lea and Leb are not proteins, and cannot, therefore, be direct gene products (although even the "protein" antigens go through post-translational modification and so also cannot, strictly speaking, be direct gene products). On top of this, of course, the mature erythrocyte has exuded all nuclear material. Antigens, therefore, should only be referred to a single or double "dose".
  14. This is an old post - in my experience the issues surrounding codabar and ISBT have resolved for labeling and have worked fine for at least the last few years. If anyone happens to remember this issue and can confirm, that would be great!
  15. This is an old topic; however, I worked with an Echo and Immucor reagents/cells and did not have any particular difficulty with rule-outs, but this was years after this post. Hopefully that means if there was an issue that it has been resolved.
  16. Last week
  17. This is an old post. Current guidelines (https://www.fda.gov/media/78536/download) indicate that donors with these results should be retested after 6 months for HCV NAT and two different, licensed anti-HCV tests. If all testing is negative at that time, the donor may be reentered. See the link for additional information.
  18. This is an old post. @js0097, if you found a solution, would you mind giving us an update?
  19. This is an old post, and I have seen this in practice a few years back. If anyone is still looking for information regarding this process or these forms, I would recommend contacting Sunquest at this point. They may have this available as an upgrade.
  20. We printed on cardstock, affixed with self-laminating sheets, and labeled with the freezer at ambient temperature.
  21. This is an old post, but a little information: acceptable false positive rates generally vary with the methodology in use and whether those rates are acceptable is decided by lab management and the medical director. Usually the frequency of positive screening tests are tracked through the LIS so trends can be identified and compared to the lab-defined thresholds to know when action is needed to address a possible issue or interferent. It's fairly easy at this point to search up the documentation on most methodologies available to see what the manufacturer obtained as far as false positive results, and the data can also be requested by contacting the company directly.
  22. This is an old topic: I haven't heard of any issues, but experience with electronics seems to point to either an internal chip/board issue or power issue. In this case, I'd be concerned that the battery connections are getting dirty in the unit, the packs aren't seating properly, or some of the internal power connections are loose or damaged. For the units with power cords, I'd also check to ensure the power cord connection to the unit isn't damaged or loose.
  23. This is an old topic: in case anyone else has the same question, we no longer used pooled platelets but billing for them used to be P9031 x 5 since the hospital is buying 5 units of platelets and then paying a processing fee to have them pooled. You should be able to verify this with the blood bank you are purchasing from. We also used CPT 86965 to pass the cost of pooling on to the insurance/patient; otherwise, the hospital would have to write off the charge since we are paying the blood provider for the service. Nearly everyone that I'm aware of is no longer using pooled platelets, however; pheresis units have been preferred and in use for a very long time now.
  24. This is an old topic, and likely most of the issues have been worked out for the major LIS systems in use. If anyone is still having challenges, I'd suggest either contacting Verax directly (they may either already have a solution or know a customer using the same LIS) or your LIS vendor (who may also already have a solution or can check their customer database for other Verax users).
  25. If you know anyone who is a member, the standards are included with their membership as a PDF; otherwise, they would have to be purchased separately. https://www.transfusion.ca/Resources/Standards
  26. Certainly this is what is recommended in the UK's BCSH (BSH) Guidelines (i.e. that they are referred to a foetal medicine unit for ultrasound monitoring) for any Kell-related antibody in pregnancy. I know this for a fact, as I was one of the co-authors!
  27. All potentially clinically significant antibodies like this can be managed pretty well by non-invasive fetal monitoring for anemia by ultrasound (doppler velocity), so the management should be the same for all such antibodies. Clinical variation is great, as you all know, so the drill is to monitor the fetus. No anemia, no worries. Anemia leads to intervention. Serology is largely irrelevant (e.g., titers) but habit is to measure them by most clinicians.
  28. There are a very few cases of severe HDFN caused by anti-Kpa (see references below). I believe that in many guidelines (to be confirmed though), antibodies to Kell blood group antigen are handled, by extrapolation, the same way as anti-K due to the very few examples reported in the literature. Costamagna L, Barbarini M, Viarengo GL, Pagani A, Isernia D, Salvaneschi L. A case of hemolytic disease of the newborn due to anti-Kpa. Immunohematology. 1997;13(2):61-2. PMID: 15387785. Tuson M, Hue-Roye K, Koval K, Imlay S, Desai R, Garg G, Kazem E, Stockman D, Hamilton J, Reid ME. Possible suppression of fetal erythropoiesis by the Kell blood group antibody anti-Kp(a). Immunohematology. 2011;27(2):58-60. PMID: 22356520. Smoleniec J, Anderson N, Poole G. Hydrops fetalis caused by a blood group antibody usually undetected in routine screening. Arch Dis Child Fetal Neonatal Ed. 1994 Nov;71(3):F216-7. doi: 10.1136/fn.71.3.f216. PMID: 7820722; PMCID: PMC1061131.
  29. Hello SoftBank users, I need guidance to set up reconstituted RBC, want to prepare by using AS3 or AS1 red cells and thawed FFP, FP24 or RT<24hr Frozen <24hr plasma. Can someone share set up of reconstituted red cells? Your help is greatly appreciated. Thanks,
  1. Load more activity
  • Advertisement

×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.